Stay invested in Sun Pharma, says Shahina Mukadam

Shahina Mukadam, Independent Market Expert told CNBC-TV18, "One should continue holding the Sun Pharmaceutical Industries. One can keep a stoploss of about Rs 700 and the target one can look at even for a year's time, in my view, would be about Rs 777-775. Basically, even if you exclude the development that happened last couple of days that is they got the approval for Gleevec that is the large product, even excluding that if you see the valuation, it is currently as of now available at about 17-18 times one year forward."She further added, "We have concerns regarding the FDA and the Halol plant exists but if one keeps a stoploss with a one-two year target, definitely those issues should be resolved and he/she should get a good return on the stock."